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Previously, we have showed that overexpression of methionine-oxidized α-synuclein in methionine sulfoxide reductase A (MsrA)
null mutant yeast cells inhibits α-synuclein phosphorylation and increases protein ﬁbrillation. The current studies show that
ablationofmouseMsrA genecaused enhanced methionineoxidation ofα-synuclein whilereducing its own phophorylationlevels,
especially in the hydrophobic cell-extracted fraction. These data provide supportive evidence that a compromised MsrA function
in mammalianbrain may cause enhanced pathologies associated with altered α-synuclein oxidation and phosphorylation levels.
1.Introduction
Parkinson’s disease (PD) is characterized by the formation of
neuronal inclusion bodies that are denoted as Lewy bodies
[1]. These bodies consist mainly of α-synuclein ﬁbrils [2].
The α-synuclein protein is a presynaptic and its function and
involvement in the development of PD is yet to be clearly
determined. When α-synuclein is abnormally expressed or
modiﬁed, various studies indicate it may cause alterations
in mitochondrial and proteasomal function, protein aggre-
gation, and accumulation of reactive oxygen species (ROS)
[3–6].
Increased ROS and cellular α-synuclein levels promote
its aggregation [7, 8] and can cause posttranslational mod-
iﬁcations to the methionine (Met) residues of α-synuclein
leading to the formation of methionine sulfoxide (MetO)—
containing α-synuclein (MetO-α-synuclein). MetO modiﬁ-
cationscanbepresentintwoformsofenantiomers: Met-S-O
and Met-R-O that can be readily reduced by the methionine
sulfoxidereductase(Msr) system.MsrtypeA(MsrA)reduces
Met-S-O and Msr type B (MsrB) reduces Met-R-O [9, 10].
MsrA i st h o u g h tt ob et h em a j o rM s rb e c a u s ei ti sa
positiveregulatorofMsrB expression levels[11,12].Absence
of MsrA can cause a hypervulnerability to conditions of
oxidative stress [13–17] and shortened lifespan [16, 18]. One
possible explanation is that the cellular regulation of aging
neurons (e.g., in PD) is altered and consequently causes the
accumulation of misfolded proteins (e.g., α-synuclein) [19].
The functional role of phosphorylation to α-synuclein is
not completely and clearly understood. Previous work has
determinedthatmsrAknockoutyeaststrainexpressing either
of the three α-synuclein types (normal type α-synuclein
(Syn) and Syn mutant types: SynA30P, SynA53T) showed
signiﬁcantly lower levels of phosphorylation relative to α-
synuclein expressed in wild-type cells [22]. These data
suggest that increased levels of MetO moiety in α-synuclein
could inhibit its phosphorylation eﬃciency, especially when
expressed in msrA-KO cells. Supportive evidence for such
possibility was demonstrated by a reduced in vitro phospho-
rylation ofthese three types ofα-synuclein by casein kinase 2
(a major kinase for α-synuclein Ser129 phosphorylation [21])
following oxidation of α-synuclein [22].
The observed decrease in α-synuclein phosphorylation
afterMetOformationwhenMsrAisablatedinyeastcellsmay
mimic processes that regulate α-synuclein phosphorylation
in mammals. Further investigations in a parallel mammalian
system will greatly contribute to clarify the physiological
role of MsrA on α-synuclein phosphorylation. Accordingly,2 Journal of Amino Acids
the goal of the current studies is to determine the levels
of MetO and α-synuclein phosphorylation in brains of
MsrA knockout (MsrA
−/−) and WT mice and evaluate their
intracorrelation.
2.Materialsand Methods
2.1. Materials. [γ-32P]-ATP (3,000Ci/mmol) was purchased
from Perkin-Elmer (Waltham, MA) and casein kinase 2 was
purchased from Millipore (Billerica, MA). Rabbit anti-MetO
antibodies were made in our lab [20] and antibodies against
α-synuclein were purchased from BD.
2.2. Methods
2.2.1. Phosphorylation of Proteins in Brains of
WT and MsrA
−/− Mouse Brains
Protein Extraction. Postmortem brains of each mouse types
(6 months of age) were homogenized at 4◦C in the presence
of 25mM Tris (pH 7.4) and protease inhibitor cocktail
(no-EDTA) (Roche, South San Francisco, CA) and 1mM
CaCl2. The extracted protein fractions were centrifuged
(15,000 × g) for 20 minutes at 4◦C, and the resulting Tris-
soluble supernatants (Sup 1) were kept and stored at −80◦C.
The pellets obtained following the centrifugation step were
redissolved in 25mM Tris (pH 7.4) and 48% Urea. Then,
the urea-soluble pellets were centrifuged again as described
above, and the resulting supernatants were dialyzed against
25mM Tris (pH 7.4) at 4◦C( S u p2 ) .
2.2.2. Phosphorylation Assay. Fifty microgram of Sup 1 and
a mixture containing 40μgo fS u p2a n d1 0 μgo fS u p1
(serving as a source for kinases) were incubated in the
presence of 25mM Tris (pH 7.4), protease inhibitor cocktail
(no-EDTA) (Roche, South San Francisco, CA), 1mM CaCl2,
10mM MgCl2, and 16.7μM[ γ-32P]-ATP (3000 Ci/ mmol)
for 3 minutes at room temperature in a ﬁnal volume of
50μL.Endogenousphosphorylationwasstoppedbyaddition
of 10mM EDTA, 10mM EGTA, and 1mM cold ATP and
immediately placed on ice. Then, the samples were subjected
to an immunoprecipitation by anti-α-synuclein antibodies
or anti-MetO antibodies as described below.
2.2.3. Isolation of Phosphorylated α-Synuclein from Brain
Extracts. Postmortem brains (n = 5) of each mouse types
were processed according to the protocol provided by the
Phosphoprotein Puriﬁcation Kit purchased from Qiagen
(Valencia, CA). Brieﬂy, each brain tissue was homogenized
using 0.25% (w/v) CHAPSsolution in lysisbuﬀercontaining
protease inhibitor cocktail and Benzonase. Following incu-
bation at 4◦C for 30min, homogenates were centrifuged at
10,000×ga n d4 ◦C for 30min. Protein concentrations of the
corresponding supernatants were determined by Coomassie
(Bradford) Protein Assay Kit (Thermo Fisher Scientiﬁc,
Rockford, IL), and 2.5mg of total protein of each lysate
was applied into the Phosphoprotein Puriﬁcation column
according to the protocol instructions. Then, the unbound
proteins were washed out from the column and the column-
bound proteins were eluted with the elution buﬀer and
concentrated using centricon with molecular cutoﬀ of 3kDa
(Millipore, Billerica, MA). Finally, equal protein amounts
(50μg) of each concentrated sample were subjected to an
SDS-PAGE (4%–20%) separation followed by Western blot
analysis using primary antibodies against α-synuclein (BD,
Franklin Lakes, NJ).
2.2.4. Immunoprecipitation or Western Blot (IP) Assays.
Immunoprecipitation was performed on brain soluble frac-
tions described above (Sup1 and Sup2) by using pri-
mary antibodies against either α-synuclein (BD, Franklin
Lakes, NJ) or antibodies against MetO [20]. The immuno-
precipitation procedure was followed according to the
immunoprecipitation kit’s protocol and related supplies
provided by Pierce Inc. Thereafter, equal protein amounts
of the immunopercipitants were subjected to an SDS-
gel electrophoresis (4%–20%) followed by either Western
blot analysis using anti-α-synuclein antibodies (as primary
antibodies) or directly exposed to X-ray ﬁlm when [γ-32P]-
ATP was used in the phosphorylation assay. The levels of
the resulting reacting bands were quantiﬁed by densitometry
analysis. In the Western blot analysis using the primary anti-
α-synuclein antibodies, normalization of the α-synuclein
detected bands in the MetO precipitants was normalized
to the levels of α-synuclein bands detected directly in each
protein extract fraction prior to the immunoprecipitation
procedure (50μgp r o t e i np e rl a n e ) .
3.Resultsand Discussion
Previously, we have showed that Met oxidation inhibits
the phosphorylation of α-synuclein both in vitro and in
ex vivo systems, in which α-synuclein was overexpressed
in yeast [22]. Complementary MsrA was able to reduce
several oxidized Met residues in recombinant α-synuclein
[23]. Similarly, studies on other proteins showed that
methionine oxidation can inhibit protein phosphorylation
[24]. In addition to the phosphorylation inhibition of α-
synuclein expressed in yeast, general protein degradation
and α-synuclein degradation were inhibited as well in this
ex vivo system while increasing protein ﬁbrillation [22]. To
establish the relationships between α-synuclein phosphory-
lation and methionine oxidation in a mammalian model,
we have monitored ﬁrst the levels of methionine-oxidized
α-synuclein in MsrA
−/− compared with control wild-type
mice. Accordingly, the levels of total α-synuclein and MetO-
α-synuclein were monitored in WT and MsrA
−/− brains
by Western blot analysis, following immunoprecipitation by
the novel anti-MetO antibodies (Figure 1(a)). The presented
data clearly show that in comparison to WT, the levels
of MetO α-synuclein are signiﬁcantly elevated in MsrA
−/−
brains both within the Tris-soluble (Sup 1) and urea-soluble
(Sup 2) fractions as demonstr a t e db yb a n dd e n s i t o m e t r y
analysis (Figure 1(b)). These results conﬁrm our initial
observation showing that the levels of MetO-containing
proteins are increased in MsrA
−/− brain [25]a n di ns e r u mJournal of Amino Acids 3
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Figure 1: Detection of methionine oxidation of α-synuclein in
MsrA
−/− and wild-type control (WT) brains. (a) Brain protein
extracts were prepared as Tris-soluble and urea-soluble fractions
from both mouse types. Equal protein amounts of the protein
extracts were either directly subjected to SDS-gel electrophoresis
and Western blot analysis (Lanes 1–4) or immunoprecipitated
by anti-MetO antibodies prior to the gel-loading (Lanes 5–8).
Lanes 1, 3, 5, and 7 represent Tris-soluble fractions, and lanes
2, 4, 6, and 8 represent urea-soluble fractions. The Western blot
analysis was probed with anti-α-synuclein antibodies as primary
antibodies. The Western blot analysis is a representative blot of
data generated from multiple experiments (n = 5). Syn, α-
synuclein;IP,immunoprecipitation;ab,antibodies; kDA,molecular
mass markers in kilo-Dalton. (b) Densitometry analysis of the α-
synuclein bands detected in (a). The percent MetO values were
calculated as percent ratio of the immunoprecipitant MetO-α-
synucleinbands(Figure 1(a),lanes5–8)tothecorrespondingbands
representing total α-synuclein levels (Figure 1(a), lanes 1–4). The
statistical diﬀerences between the MetO-α-synuclein levels in both
mouse types were signiﬁcant (n = 5; ∗P<. 0003 and ∗∗P<. 003 by
t-test).
proteins as function of age [20]. In addition, the percent
of MetO in the analyzed fractions is similar to the in vivo
MetO percentile observed in yeast cells exposed to oxidative
stress [14, 15] (the percent MetO values were calculated as
percent ratio of the immunoprecipitated MetO-α-synuclein
bands (Figure 1(a), lanes 5–8) to the corresponding bands
representing total α-synuclein levels (Figure 1(a),l a n e s1 –
4)). The next step was to evaluate the eﬀect of the observed
methionine oxidation of α-synuclein on its phosphorylation
levels in brain. To mimic in vivo phosphorylation, brain
fractions were incubated in a reaction mixture containing
[γ32P]-ATP followed by immunoprecipitation with anti-α-
synuclein antibodies or anti-MetO antibodies. Then, the
resulting precipitates were subjected to SDS-PAGE and levels
of radiolabeled proteins were detected and quantiﬁed by
exposure toX-rayﬁlm.If indeedmethionineoxidationinter-
feres with protein phosphorylation, it is expected that levels
of phosphorylation detected in the precipitated proteins will
be in inverse correlation with the levels of MetO in these
proteins. As shown in Figure 2(a), immunoprecipitation
of α-synuclein resulted in signiﬁcantly higher levels of
phosphorylated α-synuclein in the WT’s urea-soluble frac-
tion compared with the corresponding MsrA
−/− fraction.
Interestingly, phosphorylated α-synuclein was detected only
in the urea-soluble fraction and not detected in the Tris-
soluble fraction (Figure 2(a),l a n e s2a n d4 ) .T h e s er e s u l t s
conﬁrm our initial observation in the ex vivo system, in
which the phosphorylation of recombinant α-synuclein was
inhibited in msrA null mutant yeast cells [22]. Moreover, the
demonstrated enhanced protein ﬁbrillation in α-synuclein-
expressing msrA knockout yeast cells may relate to the
lower α-synuclein phosphorylation in membranal/insol-
uble MsrA
−/− fraction, as shown here in mouse brain
(Figure 2(a)). The role of phosphorylation of α-synuclein
is controversial. In vitro phosphorylation of α-synuclein at
Ser129 by casein kinase 2 forms ﬁbrils faster than non-
phosphorylatedylated α-synuclein [26] and fosters the for-
mationofcytoplasmicinclusionbodiesincellculturemodels
of synucleinopathies. However, in vivo studies showed no
obvious correlation between phosphorylated Ser129 and α-
synuclein ﬁbril formation [27]. In contrast, another study
demonstrated that phosphorylation at Ser129 inhibits α-
synuclein ﬁbril formation in vitro [28].
In light of the recent and current data, it is intriguing
to propose that phosphorylation of α-synuclein may be
a cellular compensatory attempt aimed at increasing its
solubility and preventing its aggregation. This suggested
role of α-synuclein phopshorylation is especially important
under conditions of oxidative stress that lead to enhanced
methionine oxidation. Typically, protein oxidation will cause
a Met residue to be more hydrophilic, but the overall
MetO protein may become more hydrophobic by exposing
hidden hydrophobic residues [29]. Therefore, enhanced
formation of MetO-α-synuclein (while causing its reduced
phosphorylation rate) is expected to increase its hydropho-
bic properties and as a consequence of its aggregation.
Immunoprecipitation of [γ-32P]-labeled proteins by anti-
MetO antibodies revealed a distinct protein band with a
similar molecular mass of α-synuclein (Figure 2(a),l a n e s6
and 8). To facilitate discussion, this protein band will be
denoted as MetO-15. Like shown with the [γ-32P]-labeled
α-synuclein precipitants (Figure 2(a)), the relative intensity
of this band was greater in the WT’s urea-soluble fraction
than itsparallel MsrA
−/− fraction. Althoughthe WT fraction
contains MetO proteins (as evident by the performed MetO-
protein Immunoprecipitation), the MetO residue levels in
the WT fraction are lower compared with MsrA
−/− fraction,
and thereby causing higher phosphorylation level of the
detected WT’s MetO-15 (Figure 2(a)). The identiﬁcation of4 Journal of Amino Acids
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Figure 2: Phosphorylation of α-synuclein in MsrA
−/− and wild-type (WT) brain extracts. (a) Tris-soluble and Urea-soluble brain extracts
(40μg protein) of both mouse types were prepared as described in Section 2. These extracts were then incubated in the presence of
additional brain-matched Tris-soluble extract (10μg protein, serving as a source for kinases), 25mM Tris (pH 7.4), protease inhibitor
cocktail (no-EDTA) (Roche), 1mM CaCl2,1 0m MM g C l 2 and 16.7μM[ γ-32P]-ATP for 3 minutes at room temperature in a ﬁnal volume
of 50μL. Endogenous phosphorylation was stopped by addition of 10mM EDTA, 10mM EGTA, and 1mM cold ATP and immediately
placed on ice. Then, the samples were subjected to an Immunoprecipitation by anti-α-synuclein antibodies or anti-MetO antibodies as
described in Section 2. Thereafter, equal protein amounts of the immunoprecipitants were subjected to an SDS-gel electrophoresis (4%–
20%) followed by exposure of the gel to an X-ray ﬁlm. Lanes 1, 3, 5, and 7 represent Tris-soluble fractions and lanes 2, 4, 6, and 8 represent
Urea-soluble fractions. Syn, α-synuclein; ab, antibodies; kDA, molecular mass markers in kilo-Dalton. The detected band following the
immunoprecipitation by anti-MetO antibodies was also denoted in the text as MetO-15. (b) Densitometry analysis of authoradiographed
bandsdetected in(a).Thepercent MetOvalueswere calculatedaspercent ratioofthedetected immunoprecipitant[γ-32P]-α-synucleininthe
Urea-soluble fractions,in which WT’s [γ-32P]-α-synuclein-averaged value represents 100%.The statistical diﬀerence between the [γ-32P]-α-
synuclein levels in both mouse types was signiﬁcant(n = 5; ∗P<. 05 by t-test). (c) Densitometry analysisof the phosphorylated α-synuclein
bands detected in Western blot analysis (a representative blot is shown in a small window) after isolation of phosphorylated proteins from
WTandMsrA
−/− brains(usingPhosphoProteinPuriﬁcationKit(Qiagen)).SeeSection 2forrelevantprocedures andanalyses.Thestatistical
diﬀerence between the phosphorylated α-synuclein levels in both mouse types was signiﬁcant (n = 5; ∗P<. 05 by t-test).
this MetO-15 band by mass spectrometry was not possible
due to limits of detection. However, by its molecular mass, it
seems that this protein may be either MetO-α-synuclein or a
proteinwith a similar molecularmass as previously observed
[25]. Regardless of MetO-15 identity, the phosphorylation
levels of this protein provide a good indication on the
MetO eﬀect on protein phosphorylation in each mouse
type. To better relate to the levels of brain α-synuclein
phosphorylation in each mouse type, densitometry analyses
of the phosphorylated α-synuclein bands were performed.
The averaged value calculated for the WT brain represented
a 100% phosphorylation rate (Figure 2(b)). Accordingly, the
averagedlevelofphosphorylatedα-synuclein in theMsrA
−/−
Urea-soluble fraction was inhibited by 60% in comparison
to the WT’s Urea-soluble fraction (Figure 2(b)). This MetO-
mediatedinhibitionofα-synuclein phosphorylationthrough
MsrA gene ablation is in agreement with the presence of
signiﬁcantly higher levels of in vivo methionine oxidation
of α-synuclein in MsrA
−/− brain (Figure 1). Additional
supportive evidence for this phenomenon is the observation
showing that in vivo phosphorylation of α-synuclein is lower
by 36% in MsrA
−/− compared with WT brain (Figure 2(c)).
It is suggested that a compromised MsrA function may
cause alteration of α-synuclein’s methionine sulfoxide levels
that in turn aﬀect α-synuclein’s phosphorylation levels.
Consequently, the ratio of α-synuclein’s phosphorylated
form to its nonphosphorylated form may contribute to the
progression of neurodegenerative diseases like PD.
Other in vitro eﬀects of methionine oxidation on α-
synuclein have been extensively described in the literature.
For example, the role of methionine oxidation on α-
synuclein ﬁbrillation has been studied in vitro, and it seems
that MetO inhibits α-synuclein ﬁbrillation, depending on
the environmental conditions [30–35]. In addition, it wasJournal of Amino Acids 5
reported that MetO may aﬀect dopamine binding to α-
synuclein [36, 37] and its ability to carry out one of its
proposed functions as an antioxidant [38].
In summary, it is possible that α-synuclein structure and
function may be regulated through in vivo oxidation of its
Met residues and their reversal reduction by the Msr system.
Further investigations are underway to determine if the
observed in vitro eﬀects of MetO on α-synuclein’s structure
and function can also be detected in vivo.
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